MARKET

NXTC

NXTC

Nextcure
NASDAQ
2.330
-0.460
-16.49%
After Hours: 2.290 -0.04 -1.73% 19:20 06/09 EDT
OPEN
2.850
PREV CLOSE
2.790
HIGH
2.900
LOW
2.280
VOLUME
141.62K
TURNOVER
--
52 WEEK HIGH
15.74
52 WEEK LOW
2.280
MARKET CAP
8.42M
P/E (TTM)
-0.1243
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NXTC last week (0601-0605)?
Weekly Report · 1d ago
NextCure posts Phase 1 dose-escalation data for SIM0505 in ovarian, uterine serous cancers at ASCO 2026
PUBT · 5d ago
NXTC ANNOUNCES REPLAY AVAILABLE FOR VIRTUAL KOL EVENT DISCUSSING ASCO 2026 DOSE ESCALATION DATA FROM PHASE 1 TRIAL OF SIM0505 FOR GYNECOLOGIC CANCERS
Reuters · 5d ago
What's Going On With NextCure Stock Wednesday?
Benzinga · 6d ago
NextCure posts Phase 1 SIM0505 dose-escalation presentation slides
PUBT · 06/02 13:34
NextCure share weakness overdone, says Lucid Capital
TipRanks · 06/02 10:10
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 06/01 17:06
NextCure presents Phase 1 data for SIM0505 in gynecologic cancers
TipRanks · 06/01 13:49
More
About NXTC
NextCure, Inc. is a clinical-stage biopharmaceutical company that is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of action, including antibody-drug conjugates (ADC). It focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.

Webull offers NextCure Inc stock information, including NASDAQ: NXTC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NXTC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NXTC stock methods without spending real money on the virtual paper trading platform.